319 related articles for article (PubMed ID: 23432698)
1. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
2. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management.
Cartwright TH
Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
5. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.
Troiani T; Martinelli E; Orditura M; De Vita F; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2012 Jul; 21(7):949-59. PubMed ID: 22612461
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
7. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
9. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic drugs for colorectal cancer: exploring new possibilities.
Ferrarotto R; Hoff PM
Clin Colorectal Cancer; 2013 Mar; 12(1):1-7. PubMed ID: 22763196
[TBL] [Abstract][Full Text] [Related]
11. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
12. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
15. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Grothey A
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524
[TBL] [Abstract][Full Text] [Related]
16. Challenges for patient selection with VEGF inhibitors.
Longo R; Gasparini G
Cancer Chemother Pharmacol; 2007 Jul; 60(2):151-70. PubMed ID: 17370072
[TBL] [Abstract][Full Text] [Related]
17. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
18. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
19. The present and future of angiogenesis-directed treatments of colorectal cancer.
O'Dwyer PJ
Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
[TBL] [Abstract][Full Text] [Related]
20. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
